anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: Open simple prostatectomy (OSP) has been a cornerstone in treating large prostate volumes (> 80 ml) in benign prostatic hyperplasia (BPH). With evolving minimally invasive procedures like minimally invasive simple prostatectomy (MISP) and laser enucleation, the role of OSP needs contemporary evaluation. This way, we assessed the efficacy and safety of OSP to understand its current standing in the treatment of BPH, especially in comparison with newer surgical modalities.
METHODS: A comprehensive search of MEDLINE, Cochrane and EMBASE was conducted to include randomized controlled trials (RCTs) comparing OSP with other treatments for BPH from 1993 to 2023. A total of 10 RCTs were included in the meta-analysis. Data on various outcomes including IPSS, Qmax, PVR, quality of life, perioperative factors, and postoperative complications were analysed.
RESULTS: Our meta-analysis, covering 557 patients, confirms OSP's significant improvement in voiding symptoms and objective voiding metrics. However, it also reveals a higher incidence of postoperative complications, such as bleeding and transfusion requirements. The study found moderate to high heterogeneity in perioperative outcomes, indicating variations in surgical techniques and postoperative care. OSP remains a reliable option with an easily accessible and effective approach for managing large prostates, despite advancements in minimally invasive surgeries.
CONCLUSION: OSP continues to be a relevant surgical option for BPH in large prostates, offering significant symptom relief. However, the associated higher morbidity warrants careful patient selection and highlights the need for continued research into optimizing surgical techniques and improving outcomes.
A composition containing an adhesive suitable for affixing dentures or ostomy devices to a mucous membrane, which adhesive is a mixture composed of (a) 75-25 wt. % of a blend comprising a divalent calcium salt and a monovalent sodium salt of a lower alkyl vinyl ether/maleic acid copolymer wherein the concentration of Ca is between about 10 and 15 wt. % of the blend; Na is between about 1.5 and about 4 wt. % of the blend and -COOH is between about 9 and about 25 wt. % of the blend; (b) 0-10 wt. % of a lower alkyl vinyl ether/maleic acid auxiliary metal salt wherein said metal is divalent magnesium and/or monovalent potassium and wherein said auxiliary metal represents between about 1.5 and about 15 wt. % of said auxiliary metal salt compound and (c) 25-75 wt. % of a stearic acid metal salt wherein said metal salt is magnesium stearate containing from 0% to about 75% sodium stearate. The invention also relates to the use of said composition as an adhesive used in association with mucous membranes.
The epithelial-mesenchymal transition (EMT) plays a crucial role in lung cancer metastasis, rendering it a promising therapeutic target. Research has shown that non-small cell lung cancer (NSCLC) with p53 mutations exhibits an increased tendency for cancer metastasis. However, the exact contribution of the p53-R273H mutation to tumor metastasis remains uncertain in the current literature. Our study established the H1299-p53-R273H cell model successfully by transfecting the p53-R273H plasmid into H1299 cells. We observed that p53-R273H promotes cell proliferation, migration, invasion, and EMT through CCK-8, wound healing, transwell, western blot and immunofluorescence assays. Notably, the expression of EGR1 was increased in H1299-p53-R273H cells. Knocking out EGR1 in these cells hindered the progression of EMT. ChIP-PCR experiments revealed that p53-R273H binds to the EGR1 promoter sequence, thereby regulating its expression. These findings suggest that p53-R273H triggers EMT by activating EGR1, thereby offering a potential therapeutic approach for lung cancer treatment.
Stroke and its risk factors disproportionately affect minority populations, and secondary stroke prevention programs have had relatively little success. TIA and mild stroke patients with few after-affects also stay in the hospital for a shorter period of time, and leave without enough information about their risk for another stroke. Additionally, mild stroke and TIA patients often do not follow-up with neurologists after they leave the hospital. DESERVE is a discharge education study using health workers to enroll and randomly assign 800 subjects from MSSM, MSSM Queens and CUMC diagnosed with Transient Ischemic attack (TIA ), mild Ischemic stroke (IS) or mild Intracerebral Hemorrhage (ICH) to either risk factor education or usual care. Those patients assigned to education will receive education on stroke preparedness education plus risk factor reduction education, and help accessing follow up care with health workers. This education includes a power point presentation and a patient-paced workbook and video on Risk perception, Medication Adherence, and Patient-Physician Communication. To target the most appropriate mild IS/ICH and TIA survivors for participation in this proposal, we will focus on survivors with mild stroke and TIA, excluding those whose stroke deficits are severe enough to warrant discharge to a nursing home or to require 24-hour care.

Those patients assigned to usual care will receive written stroke preparedness education. This protocol will evaluate the effectiveness of this intervention to reduce blood pressure, and individual stroke risk factors and future stroke risk. Additionally, we will evaluate the ability of the these strategies to conduct education to affect positive change in taking medications as directed, stroke knowledge 6 months and 12 months after hospital admission, attendance at follow-up health care appointments, and cost-effectiveness. After 1 year participants will be followed quarterly for up to 3 years to track events.
Intrauterine growth restriction (IUGR) and congenital anomalies are one of the important reasons for infant and childhood death, which carry a high burden to affected individuals and their families. The detection rates are increasing with the improving diagnostic techniques. There are several cohorts mentioning the screening of these diseases during pregnancy. However, at present there have been no reported relevant cohorts that study from intrauterine to extrauterine period to understand and research the occurrence and development of IUGR and congenital anomalies as well as the relationship between IUGR and the presence of congenital anomalies. So in this study, the investigators aim to conduct large-sample prospective cohort study based on clinical data and biological samples to observe the occurrences, progression and clinical outcomes of IUGR and congenital anomalies, and investigate factors, pathogenesis and prognostic biomarkers of these diseases. These results can play an important role in preventing the occurrence of IUGR and congenital anomalies, promoting prognosis and guiding the clinical treatments.

All pregnant women or neonates/infants who present to Guangzhou Women and Children's Medical Center with the diagnoses of IUGR or congenital anomalies (including congenital malformation, deformations, disruptions, dysplasia and chromosomal anomalies) are eligible to participate in the study. Investigators will use routine obstetrical ultrasound to evaluate the growths and developments of fetuses during pregnancy. Investigators will collect dietary habits, exposures (the usage of medicine, exposure to contaminants), maternal history and history of disease, imaging data from the pregnant women who are prenatally diagnosed with fetus having IUGR or congenital anomalies. Afterbirth, the neonates will receive appropriate treatment. Regular physical and neural development examination with a pediatrician to measure growth and development that has taken place. Data regarding diagnosis, treatment, growth and development will be collected by intelligent data extraction platforms. Machine learning and statistical analysis are used to build the diagnostic prediction models to improve the accuracy of prenatal diagnosis of IUGR and congenital anomalies. In addition, the investigators will estimate the burden on individuals and families by evaluating the associations between interventions during pregnancy and after birth and clinical outcomes such as adverse events, length of hospitalization, hospitalization expenses in abnormal children.

In particular, maternal blood, placenta, cord blood, child' blood, urine, stool and tissue and other specimens during hospitalization and outpatient clinical visit will be collected and stored in the biospecimen bank. biospecimen bank is managed by special accounts to ensure the correct and ethical usage of specimens. Investigators hope to identify some markers that impact the prognosis of IUGR and congenital anomalies by analyzing the prenatal and postnatal serologic data. Genetic testing will be done on some fetuses to help identify the pathogenesis and the most appropriate treatment.
Patients with EGFR-mutant NSCLC would receive bevacizumab plus third-generation EGFR-TKIs in clinical routine care. Bevacizumab 15 mg/kg or clinical routine dose would be intravenous infusion on day 1 once every 3 weeks. Osimertinib 80 mg tablets once daily would be administered.
PURPOSE: This study aimed to investigate the efficacy and safety of ultrasound-guided percutaneous radiofrequency ablation (RFA) for the treatment of synovial hyperplasia in the knee joints of antigen-induced arthritis (AIA) model rabbits.
METHODS: Forty Japanese large-eared white rabbits were divided into AIA and control groups. After successful induction of the AIA model, the knee joints were randomly assigned to RFA and non-RFA groups. The RFA group underwent ultrasound-guided RFA to treat synovial hyperplasia in the knee joint. Dynamic observation of various detection indices was conducted to evaluate the safety and effectiveness of the RFA procedure.
RESULTS: Successful synovial ablation was achieved in the RFA group, with no intraoperative or perioperative mortality. Postoperative the circumference of the knee joint reached a peak before decreasing in the third week after surgery. The incidence and diameter of postoperative skin ulcers were not significantly different compared to the non-RFA group (p > .05). Anatomical examination revealed an intact intermuscular fascia around the ablated area in the RFA group. The ablated synovial tissue initially presented as a white mass, which subsequently liquefied into a milky white viscous fluid. Gross articular cartilage was observed, along with liquefied necrosis of the synovium on pathological histology and infiltration of inflammatory cells in the surrounding soft tissue.
CONCLUSION: The experimental results demonstrated that ultrasound-guided RFA of the knee in the treatment of synovial hyperplasia in AIA model animals was both effective and safe.
Atherosclerosis (AS) is a chronic inflammatory disease involving cell death and inflammatory responses. Pyroptosis, a newly discovered pro-inflammatory programmed cell death process, exacerbates inflammatory responses. However, the roles of cathepsin B (CTSB) in pyroptosis and AS remain unclear. To gain further insight, we fed ApoE-/- mice a high-fat diet to investigate the effects and mechanisms of CTSB overexpression and silencing on AS. We also explored the specific role of CTSB in vascular smooth muscle cells (VSMCs) in vitro. The study revealed that high-fat diet led to the formation of AS plaques, and CTSB was found to increase the AS plaque lesion area. Immunohistochemical and TUNEL/caspase-1 staining revealed the existence of pyroptosis in atherosclerotic plaques, particularly in VSMCs. In vitro studies, including Hoechst 33342/propidium iodide staining, a lactate dehydrogenase (LDH) release assay, detection of protein indicators of pyroptosis, and detection of interleukin-1β (IL-1β) in cell culture medium, demonstrated that oxidized low-density lipoprotein (ox-LDL) induced VSMC pyroptosis. Additionally, CTSB promoted VSMC pyroptosis. Ox-LDL increased the expression of CTSB, which in turn activated the NOD-like receptor protein 3 (NLRP3) inflammasome and promoted NLRP3 expression by facilitating nuclear factor kappa B (NF-κB) p65 nuclear translocation. This effect could be attenuated by the NF-κB inhibitor SN50. Our research found that CTSB not only promotes VSMC pyroptosis by activating the NLRP3 inflammasome, but also increases the expression of NLRP3.
PURPOSE:To provide a hair-improving agent composed of an antibody having immunoreactivity to a protein constituting keratin-type intermediate filament, capable of improving the breaking strength of hair and effective for improving the gloss, softness, feeling, etc., of the hair. CONSTITUTION:A protein constituting keratin-type intermediate filament obtained from the human nail, body hair and hair is used as a starting material. The keratin filament is reconstructed by removing a modifying agent under reducing condition. The reconstructed filament is used as an antigen. An antibody is produced by immunizing mammals or birds with the antigen and the antibody is used as a component of the objective hair-modifying agent. The hair-modifying agent can be used in the form of shampoo, rinse, etc., by compounding to a composition for hair. The antibody has strong affinity to a completely keratinized hair and specifically binds to the hair.
808,014. Tablet; multi-layer tablet; tablet coating. HASSLE APOTEKARE P. NORDSTROMS FABRIKER A.B. Dec. 17, 1956 [Dec. 22, 1955], No. 38406/56. Class 81 (1). A method of preparing a tablet, suppository, vaginal suppository or bacilliform tablet, which may be in a multi-layer form, or a tablet coating on a core, comprises mixing a powdered soluble material which may be or may contain a medicament with a powdered insoluble non-toxic synthetic resin, preferably in a weight ratio of from 40 to 95 parts of the insoluble to 60 to 5 parts of the soluble, so that on compression the insoluble material forms a skeleton in the pores of which the soluble material is contained. Specified insoluble materials are a vinyl chloride-vinyl acetate copolymer, polyethylene, polymethyl methacrylate, polystyrene, polyvinyl acetate, cellulose acetate, urea-formaldehyde and melamine-formaldehyde resins, and preferably polyvinyl chloride. Soluble fillers specified are sodium acetate, sodium chloride, lactose and potassium sulphate. Medicaments specified are amobarbital, hexobarbital, sodium hexobarbitone, ephedrine hydrochloride, atropine, papaverine, stilboestral and nitroglycerin in alcohol. Tablets may be prepared which release medicament (a) at an even rate or (b) at a high initial rate followed by an even rate, these rates being independent of pH. Fig. 5 shows a multi-layer tablet of type (a) where the core 11 contains a mixture of ephedrine hydrochloride, sodium chloride and polyvinyl chloride, and 12 and 13 are retarding layers consisting of a mixture of sodium chloride and polyvinyl chloride. Fig. 6 shows a tablet of similar form except that the retarding layers 16 and 17 are of different thicknesses which enables a better approximation to a constant release rate to be achieved. The same results may be obtained if the retarding layers are of equal thickness but contain different amounts of soluble material or different soluble materials having different rates of solution. Fig. 10 shows a tablet of type (b) obtained by incorporating a medicament in the coating. The core 23 is the same as that in Fig. 5 with the sharp corners rounded off and the retarding layers 24 and 25 are also similar to those in Fig. 5, coated overall with a mixture of ephedrine hydrochloride, talcum, lactose and potato starch, so that on administration per os this coating 26 immediately disintegrates. In composite tablets the core may be a composition according to the invention, an ordinary tablet, or a loose powder which is compacted with the operation forming the coating. Multi-layer tablets may be made by compressing the pulverulent layers in one single compressing operation. Prolonged acting tablets may be made by first manufacturing a granulate in which the grains consist of an agglomerate of soluble and insoluble material. Moulded tablets may be heated to fuse or sinter the insoluble granules when using a thermoplastic or thermosetting material.
Study participants randomized to this arm receive ustekinumab at pre-specified timepoints during the Initial Treatment Period (16 weeks) and during the Maintenance Period. Under certain conditions participants may switch to bimekizumab dosage regimen 1 (16 weeks) and continue with bimekizumab dosage regimen 2 in the last 16 weeks of the Maintenance Period. Under certain conditions study participants may be offered to participate in the OLE Period also receiving bimekizumab dosage regimen 2.
PURPOSE: To discover a person who possibly suffers from cataract by measuring self antibody for crystal lens specific antigen in human humor by the immunity measurement method using the crystal lens specific antigen. CONSTITUTION: Crystal lens crystallin, film protein of crystal lens, and the receptacle are used for crystal lens specific antigen. Blood, plasma, and serum are used for human humor. First, the self antibody for the crystal lens specific antigen in human humor is allowed to react with the crystal lens specific antigen which is plotted at a membrane filter by the immunoblast method and is allowed to react with the crystal lens specific antigen immobilized to a solid phase by the enzyme immunoassay method. Then, a secondary antibodies for human immunity globulin which are labeled together are added and the labeled secondary antibody which is connected to the self antibody is measured.  These crystal lens specific antigen, the secondary antibody for human immunity globulin, and a color developing agent for measuring the secondary antibody are used as a reagent kit, thus measuring the self antibody and preventing the progress of cataract.
This is a phase 1 and 2 study. The phase I is a dose finding portion of the study and phase 2 will enroll additional patients at the dose found in phase I. Patients in phase I and phase 2 will have the same treatment and followup.

Participants will undergo standard of care diagnostic imaging, complete blood count (CBC) with differential and chemistry labs initially. While receiving the GCSF, participants will have a CBC with differential checked a day after each dose and one day prior to first day of radiation. The treatment planning FDG PET/CT will be performed shortly after the GCSF. During chemoradiation, participants will have weekly CBC with differential checked and other labs as standard of care.
Nanobodies are the smallest known antigen-binding molecules to date. Their small size, good tissue penetration, high stability and solubility, ease of expression, refolding ability, and negligible immunogenicity in the human body have granted them excellence over conventional antibodies. Those exceptional attributes of nanobodies make them promising candidates for various applications in biotechnology, medicine, protein engineering, structural biology, food, and agriculture. This review presents an overview of their structure, development methods, advantages, possible challenges, and applications with special emphasis on infectious diseases-related ones. A showcase of how nanobodies can be harnessed for applications including neutralization of viruses and combating antibiotic-resistant bacteria is detailed. Overall, the impact of nanobodies in vaccine design, rapid diagnostics, and targeted therapies, besides exploring their role in deciphering microbial structures and virulence mechanisms are highlighted. Indeed, nanobodies are reshaping the future of infectious disease prevention and treatment.
<P>PROBLEM TO BE SOLVED: To improve the ease of use and interoperability between multiple devices in a healthcare environment.  <P>SOLUTION: A system 100 includes an information manager 110 including clinical content, such as images and/or information, and a communication manager 140 receiving an event notification from the information manager 110. The system 100 may further include an interface 120 capable of accessing the information manager 110. Additionally, the system 100 may include a contact device capable of communicating via the communication manager 140. A modality 130 may transmit examination data to the information manager 110 and may receive instructions from the information manager 110. In an embodiment, the communication manager 140 includes a contact information list with one or more contact devices associated with a user. The communication manager 140 may be capable of detecting the presence of a user on a network.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Sodium Nitroprusside Injection is not suitable for direct injection. The solution must be further diluted in sterile 5% dextrose injection before infusion.

Sodium Nitroprusside can cause precipitous decreases in blood pressure (see DOSAGE AND ADMINISTRATION). In patients not properly monitored, these decreases can lead to irreversible ischemic injuries or death. Sodium nitroprusside should be used only when available equipment and personnel allow blood pressure to be continuously monitored. 

Except when used briefly or at low (< 2 mcg/kg/min) infusion rates, sodium nitroprusside gives rise to important quantities of cyanide ion, which can reach toxic, potentially lethal levels (see WARNINGS). The usual dose rate is 0.5 to 10 mcg/kg/min, but infusion at the maximum dose rate should never last more than 10 minutes. If blood pressure has not been adequately controlled after 10 minutes of infusion at the maximum rate, administration of sodium nitroprusside should be terminated immediately. 

Although acid-base balance and venous oxygen concentration should be monitored and may indicate cyanide toxicity, these laboratory tests provide imperfect guidance.
INTRODUCTION: SARS-CoV-2 pandemic has caused global devastations in the social, economic and health systems of every nation, but disproportionately the nations in Africa. Apart from its grave effects on the global systems, is the persistence of post-COVID-19 condition in individuals infected with the virus. Therefore, the aim of this scoping review is to collate and summarise the existing research evidence about the prevalence and health effects of post-COVID-19 infection conditions in Africa.
METHODS AND ANALYSIS: Five main databases will be thoroughly searched from 1 September 2023 to 30 April 2024, for eligible articles based on the inclusion and exclusion criteria. These databases include PubMed, Central, Scopus, Dimensions AI and JSTOR. Meanwhile, Arksey and O'Malley guidelines will guide this scoping review using article published between 1 January 2020 and 30 April 2024. This review will provide a useful insight into the prevalence of the post-COVID-19 symptoms and their health effects within the population in Africa. The results and findings of the review will be valuable for health system interventions, including restructuring and reorientation of health systems in the continent.
ETHICS AND DISSEMINATION: This scoping review will involve analysis of secondary data, therefore, no ethical approval is needed. Dissemination of the results will be done through international journals and available research conferences.
Improved approaches for accessing secured digital assets (e.g., secured items) are disclosed. In general, digital assets that have been secured (secured digital assets) can only be accessed by authenticated users with appropriate access rights or privileges. Each secured digital asset is provided with a header portion and a data portion, where the header portion includes a pointer to separately stored security information. The separately stored security information is used to determine whether access to associated data portions of secured digital assets is permitted. These improved approaches can facilitate the sharing of security information by various secured digital assets and thus reduce the overall storage space for the secured digital assets. These improved approaches can also facilitate efficient management of security for digital assets.